Abstract
ObjectiveTo evaluate the activity and safety of concurrent thoracic radiotherapy (TRT) plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used cisplatin/etoposide (PE) regimen in patients with unresectable stage III non-small cell lung cancer (NSCLC). Patients and methodsPatients were randomly assigned to receive the following treatments: PE arm, cisplatin (50mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1–5 and 29–33 plus 60Gy of TRT; PC arm, weekly concurrent carboplatin (AUC=2) and paclitaxel (45mg/m2) plus 60Gy of TRT. ResultsA total of 65 patients were randomized (PE arm, n=33; PC arm, n=32). The 3-year overall survival (OS) was significantly better in the PE arm than in the PC arm (33.1% vs. 13%, P=.04). The incidence of Grade 3/4 neutropenia was 78.1% in the PE arm and 51.5% in the PC arm (P=.05). The rate of Grade 2 or greater radiation pneumonitis was 25% in the PE arm and 48.5% in the PC arm (P=.09). ConclusionsCompared to PE regimen, weekly PC regimen cannot be recommended since it failed to achieve an improvement in either OS or PFS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
